1
|
Barace S, Santamaría E, Infante S, Arcelus S, De La Fuente J, Goñi E, Tamayo I, Ochoa I, Sogbe M, Sangro B, Hernaez M, Avila MA, Argemi J. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma. Biomolecules 2024; 14:653. [PMID: 38927057 PMCID: PMC11201933 DOI: 10.3390/biom14060653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Revised: 05/22/2024] [Accepted: 05/29/2024] [Indexed: 06/28/2024] Open
Abstract
Whole-tissue transcriptomic analyses have been helpful to characterize molecular subtypes of hepatocellular carcinoma (HCC). Metabolic subtypes of human HCC have been defined, yet whether these different metabolic classes are clinically relevant or derive in actionable cancer vulnerabilities is still an unanswered question. Publicly available gene sets or gene signatures have been used to infer functional changes through gene set enrichment methods. However, metabolism-related gene signatures are poorly co-expressed when applied to a biological context. Here, we apply a simple method to infer highly consistent signatures using graph-based statistics. Using the Cancer Genome Atlas Liver Hepatocellular cohort (LIHC), we describe the main metabolic clusters and their relationship with commonly used molecular classes, and with the presence of TP53 or CTNNB1 driver mutations. We find similar results in our validation cohort, the LIRI-JP cohort. We describe how previously described metabolic subtypes could not have therapeutic relevance due to their overall downregulation when compared to non-tumoral liver, and identify N-glycan, mevalonate and sphingolipid biosynthetic pathways as the hallmark of the oncogenic shift of the use of acetyl-coenzyme A in HCC metabolism. Finally, using DepMap data, we demonstrate metabolic vulnerabilities in HCC cell lines.
Collapse
Affiliation(s)
- Sergio Barace
- DNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain; (S.B.); (E.S.); (S.I.); (S.A.)
| | - Eva Santamaría
- DNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain; (S.B.); (E.S.); (S.I.); (S.A.)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Av. Monforte de Lemos, 3-5. Pabellón 11, Planta 0, 28029 Madrid, Spain (M.A.A.)
| | - Stefany Infante
- DNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain; (S.B.); (E.S.); (S.I.); (S.A.)
- Facultad de Medicina Humana, Universidad de Piura, Lima 15074, Peru
| | - Sara Arcelus
- DNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain; (S.B.); (E.S.); (S.I.); (S.A.)
| | - Jesus De La Fuente
- Bioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain (M.H.)
| | - Enrique Goñi
- Bioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain (M.H.)
| | - Ibon Tamayo
- Bioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain (M.H.)
| | - Idoia Ochoa
- Tecnun School of Engineering (TECNUN), University of Navarre, 31008 Pamplona, Spain;
| | - Miguel Sogbe
- Liver Unit, Tecnun School of Engineering (TECNUN), University of Navarre, 31008 Pamplona, Spain;
| | - Bruno Sangro
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Av. Monforte de Lemos, 3-5. Pabellón 11, Planta 0, 28029 Madrid, Spain (M.A.A.)
- Liver Unit, Tecnun School of Engineering (TECNUN), University of Navarre, 31008 Pamplona, Spain;
- Instituto de Investigación Sanitaria de Navarra (IdisNA), 31008 Pamplona, Spain
| | - Mikel Hernaez
- Bioinformatics Platform, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain (M.H.)
- Instituto de Investigación Sanitaria de Navarra (IdisNA), 31008 Pamplona, Spain
| | - Matias A. Avila
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Av. Monforte de Lemos, 3-5. Pabellón 11, Planta 0, 28029 Madrid, Spain (M.A.A.)
- Instituto de Investigación Sanitaria de Navarra (IdisNA), 31008 Pamplona, Spain
- Solid Tumor Program, Hepatology Laboratory, Applied Medical Research Center (CIMA), University of Navarre, C. de Irunlarrea, 3, 31008 Pamplona, Spain
| | - Josepmaria Argemi
- DNA and RNA Medicine Division, Applied Medical Research Center (CIMA), University of Navarre, 31008 Pamplona, Spain; (S.B.); (E.S.); (S.I.); (S.A.)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Av. Monforte de Lemos, 3-5. Pabellón 11, Planta 0, 28029 Madrid, Spain (M.A.A.)
- Liver Unit, Tecnun School of Engineering (TECNUN), University of Navarre, 31008 Pamplona, Spain;
- Instituto de Investigación Sanitaria de Navarra (IdisNA), 31008 Pamplona, Spain
- Division of Gastroenterology Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA 15232, USA
| |
Collapse
|
2
|
Shilbayeh SAR, Adeen IS, Ghanem EH, Aljurayb H, Aldilaijan KE, AlDosari F, Fadda A. Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism. Front Pharmacol 2024; 15:1356763. [PMID: 38375040 PMCID: PMC10875102 DOI: 10.3389/fphar.2024.1356763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Accepted: 01/24/2024] [Indexed: 02/21/2024] Open
Abstract
Background: Autism spectrum disorders (ASDs) encompass a broad range of phenotypes characterized by diverse neurological alterations. Genomic studies have revealed considerable overlap between the molecular mechanisms implicated in the etiology of ASD and genes involved in the pharmacokinetic (PK) and pharmacodynamic (PD) pathways of antipsychotic drugs employed in ASD management. Given the conflicting data originating from candidate PK or PD gene association studies in diverse ethnogeographic ASD populations, dosage individualization based on "actionable" pharmacogenetic (PGx) markers has limited application in clinical practice. Additionally, off-label use of different antipsychotics is an ongoing practice, which is justified given the shortage of approved cures, despite the lack of satisfactory evidence for its safety according to precision medicine. This exploratory study aimed to identify PGx markers predictive of risperidone (RIS) exposure in autistic Saudi children. Methods: This prospective cohort study enrolled 89 Saudi children with ASD treated with RIS-based antipsychotic therapy. Plasma levels of RIS and 9-OH-RIS were measured using a liquid chromatography-tandem mass spectrometry system. To enable focused exploratory testing, genotyping was performed with the Axiom PharmacoFocus Array, which included a collection of probe sets targeting PK/PD genes. A total of 720 PGx markers were included in the association analysis. Results: A total of 27 PGx variants were found to have a prominent impact on various RIS PK parameters; most were not located within the genes involved in the classical RIS PK pathway. Specifically, 8 markers in 7 genes were identified as the PGx markers with the strongest impact on RIS levels (p < 0.01). Four PGx variants in 3 genes were strongly associated with 9-OH-RIS levels, while 5 markers in 5 different genes explained the interindividual variability in the total active moiety. Notably, 6 CYP2D6 variants exhibited strong linkage disequilibrium; however, they significantly influenced only the metabolic ratio and had no considerable effects on the individual estimates of RIS, 9-OH-RIS, or the total active moiety. After correction for multiple testing, rs78998153 in UGT2B17 (which is highly expressed in the brain) remained the most significant PGx marker positively adjusting the metabolic ratio. For the first time, certain human leukocyte antigen (HLA) markers were found to enhance various RIS exposure parameters, which reinforces the gut-brain axis theory of ASD etiology and its suggested inflammatory impacts on drug bioavailability through modulation of the brain, gastrointestinal tract and/or hepatic expression of metabolizing enzymes and transporters. Conclusion: Our hypothesis-generating approach identified a broad spectrum of PGx markers that interactively influence RIS exposure in ASD children, which indicated the need for further validation in population PK modeling studies to define polygenic scores for antipsychotic efficacy and safety, which could facilitate personalized therapeutic decision-making in this complex neurodevelopmental condition.
Collapse
Affiliation(s)
- Sireen Abdul Rahim Shilbayeh
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Iman Sharaf Adeen
- Department of Pediatric Behavior and Development and Adolescent Medicine, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Ezzeldeen Hasan Ghanem
- Pharmaceutical Analysis Section, King Abdullah International Medical Research Center (KAIMRC), King Abdulaziz Medical City, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia
| | - Haya Aljurayb
- Molecular Pathology Laboratory, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Khawlah Essa Aldilaijan
- Health Sciences Research Center, King Abdullah Bin Abdulaziz University Hospital, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Fatimah AlDosari
- Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, Jeddah, Saudi Arabia
| | | |
Collapse
|